Business, Free News Articles, Real Estate

McCombs Properties Announces Sale of Premier Resort Development, The Reserve at Lake Travis

AUSTIN, Texas -- Today, McCombs Properties announced the sale of one of their flagship developments, The Reserve at Lake Travis. Since acquiring the land in 2008, The Reserve has become the premier resort property on Lake Travis boasting 200 plus homes, an award-winning marina, a world-class swim park and multiple amenities. With much of the development sold out, McCombs Properties is transitioning ownership to Southfork Development Partners, who have strong experience in private club hospitality, as well as resort and marina properties.

"We set out to create the finest resort community on Lake Travis and after over a decade of strong work, we've accomplished that goal. It's time to pass the baton to a successor who will not only sustain the beauty of the Reserve but build on the legacy we created," said Harry Adams, Managing Partner of McCombs Properties. "We are excited to see Southfork Development continue to improve and expand the offerings of The Reserve and make an even greater experience for our homeowners and membership," he continued.

Southfork has a 30 plus year legacy of development, construction, and operational excellence.

"We are excited for the future of The Reserve; this is a special location that has come to life with the extraordinary effort and resources of McCombs Properties. I would also like to thank team Southfork, which is home to some of the smartest and most visionary people in the development business. They have been working tirelessly behind the scenes on a vision worthy of this very special place. As an owner in the community, it will be exciting to watch their dedication and creativity come to life through the next chapter of the Reserve's story," said Brett Jensen, President of Southfork.

McCombs Properties continues to develop and operate multiple properties including their rapidly expanding Texas coastal master planned resort communities, Palmilla Beach in Port Aransas and The Reserve at St. Charles Bay in Rockport.

For more information on The Reserve at Lake Travis, visit http://www.reserveatlaketravis.com/

About McCombs Properties

Red McCombs, the founder of San Antonio-based McCombs Enterprises, is a well-respected Texas businessman, successful investor, and developer of distinctive high-profile residential and commercial properties across the Central and Southwest United States. Mr. McCombs and his handpicked managerial team at McCombs Properties bring a dedication to excellence, a detail-oriented approach, and extensive experience to every project. More importantly, what lies at the heart of every decision is that the McCombs communities create a lasting, positive legacy for generations to enjoy.

Visit https://www.mccombsproperties.com/ for more information.

Related link: https://www.mccombsproperties.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Electronics, Free News Articles, Manufacturing, Transportation

SIERA.AI Secures Major New Customers with Industry-Leading Safety Technology on Forklift Trucks

AUSTIN, Texas -- SIERA.AI a leading innovator of safety solutions for preventing industrial forklift accidents announced today that the Company has secured six (6) significant new contracts in multiple industry verticals. The six new contracts include third-party logistics, retail, food manufacturing, food service, and manufacturing.

New customers selected the SIERA.AI Safety System, S3 to prevent forklift accidents, injuries to workers and damages to the facility and forklift fleet. Customers expressed an interest to reduce facility operating costs, prevent accidents and improve all around safety in their facility. The new customers will also be able to track safety and performance for all assets regardless of location with the SIERA.AI Dashboard.

"These are important wins for SIERA.AI. Their selection proves our industry-leading safety technology produces significant value," said Saurav Agarwal, president and CEO of SIERA.AI. "ProMatDX will be a valuable platform delivering our message of innovative safety solutions that positively impacts the industrial market's bottom line."

SIERA.AI is a sponsor for the upcoming ProMatDX show from April 12-16, 2021. The Company's forklift safety presentation is on Friday, April 16, 2021 from 1:30 - 1:45 CST.

About SIERA.AI

SIERA.AI believes in the Power of One. Our goal is to remove one barrier at a time with innovative solutions that empower and safeguard company assets and protect their employees so they can focus on what they do best. We accomplish this by integrating technologies such as machine vision, IoT sensors and AI to prevent accidents before they even happen. For more information visit https://www.siera.ai/.

Media Contact for SIERA.AI
Cherise Kennerley
cherise@siera.ai
847-312-1367 mobile

Related link: https://www.siera.ai/

This news story was published by the Neotrope® News Network - all rights reserved.

Advertising and Marketing, Business, Free News Articles, Sports and Activities

Kalyagen Announces Release of ‘The Stemregen Effect’ Commercial with Three Former UCLA Players to Coincide with the Bruins Advancing to the Final Four

AUSTIN, Texas -- Kalyagen™ is pleased to announce the release of its "The Stemregen Effect" social media ad featuring former UCLA Bruins and NBA players Niguel Miguel, Marques Johnson and Mitchell Butler to promote STEMREGEN®, a natural stem cell enhancer documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM).

"We were delighted to have three generations of former NBA players participate in the first ad of our "Stem the Tide of Time" campaign," said Christian Drapeau, CEO and Chief Scientist of Kalyagen™. "We are doubly pleased to be able to showcase this ad as these three former UCLA basketball standouts celebrate UCLA's appearance in the Final Four and demonstrate how Stemregen has been able to help them to stem the tide of time."

The ad, part of the "Stem the Tide of Time" campaign designed to increase awareness of STEMREGEN®, is being released to coincide with the Bruins first Final Four appearance since 2008.

"Years of jumping and running up and down high school, UCLA and NBA floors have taken their toll on all of us," said Nigel Miguel. "I couldn't be happier to show what 'Stem the Tide of Time' means for me along with my former UCLA colleagues Marques and Mitch at the same time the Bruins are about to play in the Final Four. And yes, Marques can still dunk at 65!"

STEMREGEN® is a unique and patent-pending blend of proprietary plant-based extracts documented to support ESCM and increase the number of circulating stem cells, supporting the natural ability of the body to repair and stay healthy. Ingredients in STEMREGEN® have been investigated in more than eight studies for their effect on stem cell function, of which five were randomized, double- blind, placebo-controlled human clinical trials. STEMREGEN® has wide application in antiaging and overall health maintenance.

About Kalyagen

Kalyagen™ was founded by Christian Drapeau, author of the bestseller Cracking the Stem Cell Code. Kalyagen is a leader in the research and development of natural products aimed at supporting stem cell function of the body. Stem cells constitute the natural repair system of the body, and stem cell enhancers have been documented to strongly contribute to improving health and quality of life. STEMREGEN® is the first product developed by Kalyagen™. STEMREGEN® is a unique blend of proprietary plant-based extracts documented to support Endogenous Stem Cell Mobilization and provide other health benefits.

For more information, please visit our Website: http://www.kalyagen.com/

About Nigel Miguel

Nigel Miguel was the first Belizean to play in Division I sports. In his final season with the UCLA Bruins, Mr. Miguel earned All-Pac-10 honors and was also named Pac-10 Defensive Player of the Year while helping lead the Bruins to the 1985 National Invitation Tournament championship. Best known for his role as "Dwight the Flight" in White Men Can't Jump, Mr. Miguel has been in numerous television and movie productions, both in front and behind the camera. Mr. Miguel currently serves as Film Commissioner for Belize.

VIDEO (YouTube): https://tinyurl.com/cn7k4mat

MEDIA CONTACT:
Biomics, LLC (dba Kalyagen™)
Herbert Dogan, Chief Marketing Officer (310-433-8072)
hgd@kalyagen.com

Social media: @kalyagen #stemthetideoftime #stemthetide

DISCLAIMER: None of the statements contained in this press release have been evaluated by the Food and Drug Administration. The products and information in the release are not intended to diagnose, treat, cure or prevent any disease.

*PHOTO link for media: https://www.Send2Press.com/300dpi/21-0403s2p-kalyagen-players-300dpi.jpg

*Caption: (L-R) Mitchell Butler, Marques Johnson and Nigel Miguel on camera for "The Stemregen Effect."

Related link: https://www.kalyagen.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Free News Articles, Product Launches

Pure MHC, LLC Announces Launch of Contract Research Service Division and Initial Collaboration Project with argenx

AUSTIN, Texas -- Pure MHC, LLC, a target discovery and development company, today announced the launch of its contract research services arm, Pure MHC Solutions, and an initial collaboration project with global immunology company, argenx.

Pure MHC Solutions will provide collaborators access to Pure MHC's unique tools, experience, intellectual property, and infrastructure in HLA peptide target discovery, presentation, validation, and related competencies in a discrete, project-based manner. Pure MHC's core technologies are broadly applicable for oncology, autoimmune, and infectious disease indications.

Using its proprietary suite of intellectual property and related tools, Pure MHC Solutions works with partners seeking to elucidate how drugs and immune therapies alter, block, or enhance HLA antigen presentation to T-cells. This information can be used to determine a drug's potential efficacy, its mechanism of action, or to assist in defining the potency and tuning strategies for novel therapeutics.

Additional services and tools offered by Pure MHC Solutions also include its Peptide HLA Immunotherapy Data Resource ("PHIDR"), which is a proprietary healthy tissue database and repository used to guide TCR-based immune therapies to disease-specific targets by eliminating HLA/peptide complexes found on healthy tissues.

Pure MHC Solutions' project with argenx will support a more robust understanding of how antigen presentation changes in the presence of specific therapeutic agents, enabling more dynamic decision-making for its therapeutic programs.

"We are excited to offer our unique set of tools and services to collaborators such as argenx to assist with their autoimmune therapy programs," said Pure MHC President Kris Looney, "Pure MHC Solutions is uniquely positioned to provide access to these tools and has the deep HLA expertise that we believe will help drive better outcomes not only for our partners, but ultimately, for their patients."

About Pure MHC

Pure MHC, LLC is a platform technology company funded and managed by Emergent Technologies, Inc. with expertise in disease-specific target identification and validation as well as immunotherapeutic drug development for cancer, infectious and autoimmune diseases and allergy. The Pure MHC target discovery technology was developed by Chief Scientist William Hildebrand, Ph.D., of the University of Oklahoma Health Sciences Center. Visit: www.puremhc.com

About Emergent Technologies

Emergent Technologies, Inc. is an innovation solutions and technology commercialization leader headquartered in Austin, Texas. Visit: www.etibio.com

Related link: https://puremhc.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Free News Articles, Surgery and Neurotechnology

Pure Transplant Solutions Announces Collaboration with Innobiochips to Develop Personalized Diagnostics for Post-Transplant Monitoring and Early Detection of Transplant Rejection

AUSTIN, Texas -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with Innobiochips (IBC), a developer of innovative immunoassays and the SirYus™ diagnostic platform technology, to develop personalized HLA diagnostics that will detect and quantify donor specific antibodies (DSA's) in post-transplant settings and provide the basis for post-transplant monitoring and early detections of transplant rejection.

The research is being led by Innobiochips co-founders Drs. Vianney Souplet and Christophe Olivier, and Dr. Rico Buchli, VP of Products and Services at PTS. The collaboration aims to develop and validate new individualized, allele specific HLA-antibody diagnostics. The initial goals of the collaboration are to quickly develop the first commercial prototype and gather the data needed to validate the platform with leading community experts. The companies are optimistic that they will be able to rapidly provide a new portfolio of allele specific diagnostics to HLA lab directors, transplant clinicians and transplant patients that do not currently exist. These new diagnostics would enable personalized, easy to use, and quantifiable sequential monitoring of patient specific DSA levels, the result of which would provide a new pro-active window for clinicians to implement earlier graft saving interventions for transplant recipients.

"Between our two companies, we feel that we already have the ingredients needed to provide a new set of tools to those who care for transplant patients," Dr. Buchli stated. "Our proteins solve a number of important challenges on the serological side while the Innobiochips SirYus platform provides a very easy to use and elegant way to manufacture discrete, allele specific tests with the necessary controls, it really is a powerful combination."

"Over the past years, our companies have been exploring ways to combine our complementary technologies to create breakthrough diagnostics in the transplant market. PTS has the in-depth knowledge in HLA proteins and IBC has demonstrated that its technology is incredibly flexible and can enable as many as 144 serological assays at the same time in a single well, providing the transplantation departments an outstanding and new solution for HLA detection," Dr Souplet stated.

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation.

Learn more: https://www.puretransplant.com/

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its new ecommerce website, www.hlaprotein.com, Pure Protein now offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About Innobiochips

Innobiochips is a diagnostic company committed to provide innovative multiplex immunoassays and aims to position its technology, SirYus™, as a new standard for In Vitro Diagnostics. As of today, Innobiochips has developed and produces products dedicated to transplantation and immunodeficiency and is partnering with several major players to incorporate the SirYus technology into larger IVD applications.

Related link: https://www.puretransplant.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Free News Articles, Surgery and Neurotechnology

Pure Transplant Solutions Announces Collaboration with Northwestern University to Develop Novel Reagents for Enhanced Characterization of HLA DQ Antigens in Transplant Rejection

AUSTIN, Texas -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with Northwestern University, a world leader in HLA DQ antigen research.

The focus of the collaboration is to develop and test novel HLA reagents created by PTS that may be used for enhanced analysis and characterization of DQ antigens, an HLA Class II type that is increasingly gaining importance in causing rejection in transplant patients.

The research is being led by Dr. Anat Tambur, Director of the Transplant Immunology Laboratory and Comprehensive Transplant Center at Northwestern University Feinberg School of Medicine, and Dr. Rico Buchli, VP of Products and Services at PTS.

"The Tambur lab at the Comprehensive Transplant Center, Northwestern University, Chicago, is focusing on understanding the immunogenicity of HLA-DQ antigens and its role in antibody-mediated rejection in solid organ transplantation," said Dr. Tambur. "Increasing evidence has demonstrated that DQ mismatches between transplant recipient and donor are the most common to induce de novo donor-specific antibodies (DSA). HLA-DQ antibodies are likely also the most detrimental to graft survival. Understanding the unique structural and molecular properties that make the HLA-DQ molecule so pathogenic may eventually help us better predict which mismatches will induce harmful antibody formation, and which are more permissible. This work requires availability of purified HLA-DQ and other HLA class II molecules, maintaining high physiologic accuracy of the three-dimensional structure. Our collaboration with Pure Transplant Solutions allows us to develop unique approaches to study the unique involvement of HLA-DQ in transplant immunology."

"In the last years, we have seen a re-emerging role of HLA-DQ in transplantation medicine with increasing evidence that DQ mismatches between transplant recipient and donor are most detrimental to graft survival," said Dr. Buchli. "Our panel of highly representative HLA-DQ alleles will help to drive novel research to prevent transplant rejection and to contribute to more insight into DSA responses and we are thrilled to be working with Dr. Tambur, a world leader in this field."

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Visit: www.puretransplant.com

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its new ecommerce website, www.hlaprotein.com, Pure Protein now offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

Related link: https://www.puretransplant.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Drugs and Pharmaceuticals, Free News Articles, Product Launches

Pure MHC, LLC Announces Launch of its Peptide HLA Immunotherapy Data Resource following Collaboration with LifeNet Health

AUSTIN, Texas -- Pure MHC, LLC, a target discovery and development company, today announced the launch of its Peptide HLA Immunotherapy Data Resource ("PHIDR"), built through its collaboration with a trusted provider of transplant solutions and a leader in regenerative medicine, LifeNet Health.

The PHIDR healthy tissue database and repository will guide T Cell Receptor (TCR)-based immune therapy development to disease-specific targets by enabling developers to identify HLA/peptide complex targets found on healthy tissues. By screening potential target candidates against PHIDR, developers can confidently select, qualify, and focus efforts on those biomarker targets that minimize off-target or bystander effects.

The PHIDR database is representative of the full healthy human immunopeptidome as it includes HLA/peptide complexes expressed on multiple tissue samples from all over the body, with a focus on the vital organs. In addition to the peptide database, PHIDR includes a repository of matched cryopreserved tissue samples that enable complimentary orthogonal target validation techniques, including proteomics-based target quantification, genomics, and transcriptomics, on an as-needed basis.

For nearly 40 years, LifeNet Health has advanced medicine through the life-changing power of organ and tissue donation. Thanks to selfless donors, scientific discovery is advanced.

LifeNet Health LifeSciences has accelerated preclinical research and discovery through its growing portfolio of primary human cells and biospecimens for solutions that expedite research and allow the scientific community to develop and enhance new, safe therapies and medical breakthroughs.

"We are excited to offer access to the PHIDR database and repository to collaborators through our Pure MHC Solutions contract research arm," said Pure MHC President Kris Looney. "We could not have successfully built this resource without our collaborators at LifeNet Health. To be able to develop such a valuable resource for therapeutic development aligns nicely with LifeNet Health's mission to help patients live longer, healthier, and enjoy more active lives."

"We are proud to partner with Pure MHC and congratulate them on achieving success in their research efforts. Thanks to selfless donors, LifeNet Health is able to offer partners more than 40 types of biospecimens for research with over 200 protocols in place to meet the individual needs of researchers advancing scientific discovery," said Louis Dias, Vice President and General Manager of LifeNet Health LifeSciences. "The LifeNet Health LifeSciences team provides access to rare patient disease populations and enables researchers to unlock discoveries faster and with greater precision - offering the hope of new therapies to patients in need."

About Pure MHC

Pure MHC, LLC is a platform technology company funded and managed by Emergent Technologies, Inc. with expertise in disease-specific target identification and validation as well as immunotherapeutic drug development for cancer, infectious and autoimmune diseases and allergy. The Pure MHC target discovery technology was developed by Chief Scientist William Hildebrand, Ph.D., of the University of Oklahoma Health Sciences Center. Visit: www.puremhc.com

About LifeNet Health LifeSciences

LifeNet Health LifeSciences is an innovative leader, trusted collaborator, and reliable solutions provider - committed to advancing science, accelerating discovery, and optimizing outcomes. Leading the way in human in vitro biology, LifeSciences' game-changing innovations, currently under development, include models for the metabolic disease and oncology therapeutic areas and their related tools. For more information, go to www.LNHLifeSciences.org.

About Emergent Technologies

Emergent Technologies, Inc. is an innovation solutions and technology commercialization leader headquartered in Austin, Texas. Visit: www.etibio.com

Related link: https://puremhc.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Drugs and Pharmaceuticals, Free News Articles, Patent and Trademark

Zeteo Biomedical Receives US Patent for Innovative Sublingual Delivery Device for Vaccines and Pharmaceuticals

AUSTIN, Texas -- Zeteo Biomedical, a privately held, biomedical device company, announced today it has been awarded a United States Patent for its "Oral Delivery Device and Methods" (US Patent 10238577). This latest patent expands the capabilities of Zeteo's ZEOx1™ Delivery Platform to systemically deliver drugs or biologics, into the body non-invasively via the sublingual route.

Sublingual delivery has emerged as a viable route of administration for vaccines and medications for pain, cardiovascular, allergy, seizure, sedation and emesis. The sublingual route avoids first pass metabolism and provides rapid systemic uptake into the body providing advantages over traditional oral medications.

Zeteo's latest innovations expand its ZEOx1 Hydra™ sublingual delivery device family that include configurations for mono-dose disposable and mono-dose reloadable dispensers for vaccines, drugs, biopharmaceuticals, biologics and botanical liquid formulations. "We see expanding demand for metered dose sublingual delivery devices that are easy to use, convenient to carry, deliver a precise dose and can be self-administered," said Timothy Sullivan, President of Zeteo Biomedical.

Zeteo's delivery device technology and product integration services enable pharmaceutical and biotech manufacturers to develop drug/device combination products that can extend or establish market exclusivity and competitive differentiation for new or existing drugs and biologics. The shift to developing value added, patient-centric products benefit the consumer through improved compliance and health outcomes while building brand value for the pharmaceutical or biotech manufacturer. Zeteo's delivery platforms and products are designed to meet the diverse demands of consumers and pharma manufacturers in globally competitive markets.

About Zeteo Biomedical LLC

Zeteo Biomedical™ is a biomedical device technology company based in Austin, Texas. Zeteo provides patient-centric delivery device technology and unit dose fill/finish packaging for pharmaceuticals, biopharmaceuticals, biologics and botanicals for intranasal, nose-to-brain, ophthalmic, sublingual, and animal care product applications.

For more information, please visit the Zeteo website at: https://www.zeteobiomed.com/

Media Contact
Cathy Diehl
Zeteo Biomedical LLC
+(1) 512-614-0144
zeteo@zeteobiomed.com

*LOGO link for media: https://www.send2press.com/300dpi/20-1117s2p-zeteo-biomedical-300dpi.jpg

Related link: https://www.zeteobiomed.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Awards and Honors, Business, Free News Articles, Manufacturing

SIERA.AI Named a Finalist for Best New Product for the 2021 MHI Innovation Awards

AUSTIN, Texas -- SIERA.AI, a leading innovator for safety solutions, leveraging machine vision, IoT sensors and AI technologies to prevent forklift accidents, was named a finalist in the "Best New Product" category for material handling, logistics and supply chain professionals by MHI. SIERA.AI joins a list of distinguished finalists including SVT Robotics, ThruWave, Vecno Robotics and Wiferion GmbH, chosen from a field of 92 submissions.

"SIERA.AI is honored to be an Innovation Awards finalist," said Saurav Agarwal, President and CEO, SIERA.AI. "We have an incredible, talented team whose passion, endless energy and dedication help create an environment where innovation, creativity and collaboration thrive."

SIERA.AI's new standard for lift truck safety ensures safety in the warehouse, distribution center or manufacturing facility. The S3 Proximity Warning & Impact Monitoring works on any gas, electric or LP lift truck. The system monitors around the lift truck with audible and visual alerts. S3 with Slow to a Safe Stop for electric lift trucks ensures maximum workplace safety.

If a pedestrian, product or vehicle gets within the defined distance, and the operator is unaware, the S3 overrides the driver and automatically slows down and comes to a safe stop. All incidents are reported in our cloud-based dashboard, ready for analysis to ensure OSHA forklift safety standards.

The MHI Innovation Awards educates and provides insights on the latest material handling and supply chain products and services to ProMatDX attendees. ProMatDX is a digital event for manufacturing and supply chain professionals with critical access to the latest solutions to improve resiliency and agility of their operations. SIERA.AI is a sponsor for the event.

About SIERA.AI

SIERA.AI believes in the Power of One. Our goal is to remove one barrier at a time with innovative solutions that empower and safeguard company assets and protect their employees so they can focus on what they do best. We accomplish this by integrating technologies such as machine vision, IoT sensors and AI to prevent accidents before they even happen. For more information visit https://www.siera.ai/.

Related link: https://www.siera.ai/

This news story was published by the Neotrope® News Network - all rights reserved.

Free News Articles

Governor Abbot’s Disaster Declaration Recognizes Dire Relief Support but the Texas Department Licensing and Regulation’s (TDLR) Responsive Mold Regulation Changes Wrongly Backs Emergency Licensed Mold Remediation Efforts, a Threat to Public Health and Safety

AUSTIN, Texas -- In response to the announcement issued by Governor Abbot on February 12, 2021, in regard to the severe winter weather that caused statewide damage, the Texas Mold Assessors and Remediators Association (TMARA), the leading professional organization dedicated to protecting consumers throughout Texas, issued the following statement:

Statement by Mike Marshall, President, TMARA:

"At TMARA, we continue to fight for the regulation of our mold industry to protect consumer health, safety and financial well-being. While we understand the need for Governor Abbot's call to action and the support of our fellow mold professionals, the mold regulations should not change to grant emergency licensed contractors the ability to perform mold remediation without an independent mold assessment, mold remediation protocols in place and standard reporting requirements as outlined in the Texas Mold Regulations.

Repairs are just getting started, and property owners need to be aware that they do not want just anyone addressing a potential mold issue. They must seek someone who is qualified, licensed and working inside the mold regulations set forth by the State of Texas. By using an emergency licensed mold remediation contractor, property owners may not be able to obtain a protocol that outlines the steps on properly removing mold from a property, nor will property owners be able to receive a signed Certificate of Mold Damage Remediation (CMDR) without the requirement of having their entire property inspected and cleared, not merely the mold-impacted areas. The CMDR provides property owners and potential future buyers with a level of assurance that a mold issue has been eliminated and the underlying cause has been remedied. As outlined on the Consumer Mold Information Sheet (CMIS), a TDLR publication, 'Receiving a certificate documenting that the underlying cause of the mold was remediated is an advantage for a homeowner. It prevents an insurer from making an underwriting decision on the residential property based on previous mold damage or previous claims for mold damage. If you sell your property, the law requires that you provide the buyer a copy of all certificates you have received for that property within the preceding five years.' https://www.tdi.texas.gov/orders/co-03-1223.html

Unfortunately, we have seen these types of scenarios before. Someone uses an unqualified professional, and a few months down the road, a state-licensed mold assessor or remediator comes back to find a 'remediated' property worse off than it was from the initial damage. In fact, many of us are still addressing these same types of issues from Hurricane Harvey.

For property owners or professionals who want advice on the right way to move forward, consumers must:
* Contact a qualified water mitigation company and/or start drying out their home or building.
* If mold is suspected, contact a state-licensed mold assessment company or consultant to perform an initial mold assessment, obtain a protocol for mold remediation, hire a state-licensed mold remediation contractor to perform the remediation, have a Post Remediation Mold Assessment done and receive a Certificate of Mold Damage Remediation.
* To confirm the license status of a potential company or contractor, we recommend visiting https://www.tdlr.texas.gov/licensesearch/.

TMARA supports granting emergency licenses because given our state of emergency, mold professionals are in high demand. We do not support waving the other regulations that ensure consumer safety. We call on Governor Abbot to mandate that TDLR requires all emergency personnel to prove they meet our state qualifications and to require these emergency licensees to follow the same mold regulations that are required of the state licensees that support the millions of Texans that are affected by this disaster. Time and time again, we fight this battle, many state officials agree, and yet here we are once again risking the health and safety of the people of the great state of Texas."

More About TMARA:

Located in Austin, the Texas Mold Assessors and Remediators Association is the leading trade association in Texas with member companies making up the largest portion of the mold inspection and remediation marketplace in the state. TMARA was formed during the 86th Texas Legislation period when bills were proposed in both the Texas state Senate and House of Representatives to deregulate the mold industry. Our voices were heard, and those bills were not adopted, but our work is far from over. Members who gathered during that period saw not only a threat to industry standard but a need to fight irreversible change that would endanger public health and the livelihood of hundreds of licensed professionals. With a mission to continue to cultivate responsible mold inspections and remediations, TMARA offers an unparalleled commitment to a professional culture of credibility by maintaining regulation and high ethical practices. For more information, visit https://tmara.org.

Related link: https://tmara.org/

This news story was published by the Neotrope® News Network - all rights reserved.